Multimodal HDAC Inhibitors with Improved Anticancer Activity

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Cancer Biology

Background:

• Histone deacetylases (HDACs) are crucial regulators of gene expression implicated in cancer progression.
• The approved HDAC inhibitor vorinostat, a hydroxamate derivative, faces challenges like drug resistance and increased tumor aggressiveness.
• There is a need for novel HDAC inhibitors that circumvent the limitations of existing hydroxamate-based therapies.

Purpose of the Study:

• To review the chemistry and anticancer mechanisms of novel multimodal HDAC inhibitors.
• To highlight strategies for overcoming resistance associated with traditional HDAC inhibitors.
• To explore the pleiotropic anticancer effects of these new drug candidates.

Main Methods:

• Review of recent scientific literature on HDAC inhibitors.
• Analysis of the chemical structures and synthesis of multimodal HDAC derivatives.
• Examination of preclinical data on the anticancer activity and mechanisms of action.

Main Results:

• Development of novel HDAC inhibitors with diverse zinc-binding groups beyond hydroxamates.
• Demonstration of promising anticancer activity in preclinical models.
• Identification of multimodal mechanisms contributing to their efficacy.
• Overcoming acquired or intrinsic drug resistance observed with older HDAC inhibitors.

Conclusions:

• Novel multimodal HDAC inhibitors represent a promising advancement in epigenetic cancer therapy.
• These compounds offer potential solutions to the resistance and aggressiveness issues associated with hydroxamate-based HDAC inhibitors.
• Further research into their chemistry and diverse mechanisms of action could lead to more effective cancer treatments.